INVA · NASDAQ · Biotechnology

Innoviva (INVA)

Funds hospital critical-care and infectious-disease drugs with GSK respiratory royalties.

$20.68
vs last close−0.30 (−1.42%)
  1. Innoviva (INVA) Tops Q1 Earnings Estimates

    Zacks Investment Research